Manila Times Business
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in EuropeGross proceeds could amount to €19.3 million based on current share price1 over a 24-month periodCash runway to be extended to end of December 2026Subsequent filing of the 2025 Universal Registration Document now scheduled on June 3, 2026, to include this financingNANTES, France, May 28, 2026 - 9:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mn
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago